https://www.scmp.com/rss/517902/feed Sino Biopharmaceutical develops, manufactures and markets pharmaceuticals, biopharmaceuticals and Chinese medicines. It offers products to treat conditions ranging from hepatitis to respiratory and digestive diseases. It is a subsidiary of Thailand's Charoen Pokphand Group. en https://assets.i-scmp.com/static/img/icons/scmp-meta-1200x630.png https://www.scmp.com Daniel Ren Daniel Ren The cross-border outlicensing activities of Chinese biotech firms reached a record transaction value of US$60 billion in the first quarter of 2026, driven by multinational pharmaceutical companies’ growing appetite for the country’s promising drug candidates. The deal value represented a 73 per cent jump from the same period a year earlier, and accounted for nearly half of the total US$135.7 billion worth of agreements signed throughout 2025, the National Medical Products Administration (NMPA)... https://www.scmp.com/business/china-business/article/3348295/china-biotech-deals-hit-record-innovative-drugs-draw-interest-multinationals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3348295/china-biotech-deals-hit-record-innovative-drugs-draw-interest-multinationals?utm_source=rss_feed Sun, 29 Mar 2026 11:26:21 +0000 Julie Zhang Julie Zhang Mainland Chinese investors can now buy shares in more than a dozen newly added Hong Kong-listed biotech and pharmaceutical companies after a reshuffle of the Stock Connect southbound trading list took effect on Monday, reflecting the sector’s growing role on the international stage. Foreign capital, however, remained cautious, analysts said. “Mainland buyers have been the main force behind the latest healthcare rally. They tend to chase smaller-cap names where a tight free float makes it easier... https://www.scmp.com/business/china-business/article/3346016/china-investors-energise-hong-kong-biotech-stocks-foreign-money-missing-out?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3346016/china-investors-energise-hong-kong-biotech-stocks-foreign-money-missing-out?utm_source=rss_feed Mon, 09 Mar 2026 23:30:07 +0000 Julie Zhang Julie Zhang The pace and size of outlicensing deals between Chinese drug makers and global partners have accelerated this year, highlighted by two agreements announced this week, each worth more than US$1 billion. The string of deals shows how China is becoming a sought-after source of drug candidates for multinational pharmaceutical companies, which are increasingly looking for long-term partnerships rather than one-off arrangements, analysts said. The latest deals, Sino Biopharmaceutical’s agreement with... https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3345404/china-outlicensing-tops-us52-billion-first-two-months-rise-global-deals?utm_source=rss_feed Wed, 04 Mar 2026 09:30:11 +0000 Julie Zhang Julie Zhang As Chinese biotech and pharmaceutical firms gain importance on the global stage, foreign investors from sovereign wealth funds to industry players are securing strategic stakes in their future success. International institutional investors have built up significant positions in Chinese biotech firms over the past decade. These positions often approach, and in some cases exceed, the 5 per cent disclosure threshold for substantial shareholders in Hong Kong. BlackRock, the world’s largest asset... https://www.scmp.com/business/china-business/article/3340801/revealed-global-funds-blackrock-temasek-back-chinas-largest-biotech-firms?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3340801/revealed-global-funds-blackrock-temasek-back-chinas-largest-biotech-firms?utm_source=rss_feed Fri, 23 Jan 2026 00:30:09 +0000 Zhang Shidong Zhang Shidong Hong Kong stocks closed higher on the last full trading day of the year on Tuesday, as investors geared up for more clarity on policy signals in 2026 and the Chinese yuan strengthened to its strongest level in more than two years. The Hang Seng Index rose 0.9 per cent to 25,854.60 at the close. The Hang Seng Tech Index gained 1.7 per cent. On the mainland, the CSI 300 Index added 0.3 per cent and the Shanghai Composite Index finished almost unchanged. A strengthening yuan boosted the appeal of... https://www.scmp.com/business/china-business/article/3338089/hong-kong-stocks-trade-narrow-range-last-full-trading-day-year?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3338089/hong-kong-stocks-trade-narrow-range-last-full-trading-day-year?utm_source=rss_feed Tue, 30 Dec 2025 02:22:58 +0000 Julie Zhang Julie Zhang China is gaining a solid reputation as a pharmaceutical innovation hub, shifting from a copycat drug maker to one whose infrastructure and research and development capabilities rival global pharmaceutical behemoths, according to a global consultancy. US-based SAI MedPartners and its unit Idea Pharma recently launched a new index with the aim of highlighting Chinese drug makers and recognising their shift from generics to “true” innovation. The consultancy released the China Pharmaceutical... https://www.scmp.com/business/china-business/article/3336851/chinas-pharmaceutical-sector-moves-big-leagues-global-innovation-powerhouse?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3336851/chinas-pharmaceutical-sector-moves-big-leagues-global-innovation-powerhouse?utm_source=rss_feed Fri, 19 Dec 2025 00:30:08 +0000 Eric Ng,Julie Zhang Eric Ng,Julie Zhang When Zhao Hong, chief doctor of China’s leading cancer hospital at the Chinese Academy of Medical Sciences, told his fellow delegates at a Communist Party meeting in March that a little-known Guangzhou biotech firm’s cancer drug had beaten the world’s bestselling medicine, investors took notice. “As a long-serving front-line doctor, my most profound feeling is that China is at the best time of its biopharmaceutical sector’s development,” he told state media on the sidelines of the annual Chinese... https://www.scmp.com/business/china-business/article/3327701/chinas-biotech-renaissance-rising-drug-creation-prowess-attracts-global-notice?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3327701/chinas-biotech-renaissance-rising-drug-creation-prowess-attracts-global-notice?utm_source=rss_feed Sat, 04 Oct 2025 02:00:09 +0000 Zhang Shidong Zhang Shidong A rally that sent Hong Kong stocks to the highest level in four years took a breather, as Chinese drug makers took a pounding amid fears that the Trump administration would impose fresh curbs on medicine exports from the country. The Hang Seng Index closed 0.4 per cent lower at 26,086.32 on Thursday, trimming a decline of as much as 1.2 per cent. The Hang Seng Tech Index slipped 0.2 per cent. A rebound in mainland stocks helped to ease the selling pressure in the city. The CSI 300 Index climbed... https://www.scmp.com/business/china-business/article/3325115/hong-kong-stocks-slip-4-year-high-amid-fears-us-sanctions-chinese-drug-makers?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3325115/hong-kong-stocks-slip-4-year-high-amid-fears-us-sanctions-chinese-drug-makers?utm_source=rss_feed Thu, 11 Sep 2025 02:33:19 +0000 Zhang Shidong Zhang Shidong Hong Kong stocks kicked off the week with a gain on Monday after soft economic data and declining home prices in mainland China increased bets on more forceful policy support. The Hang Seng Index rose 0.7 per cent to 24,060.99 at the close, ending a two-day decline triggered by the military strikes in the Middle East. The Hang Seng Tech Index gained 1.2 per cent. On the mainland, the CSI 300 Index advanced 0.3 per cent, and the Shanghai Composite Index added 0.4 per cent. Gold jeweller Chow Tai... https://www.scmp.com/business/china-business/article/3314547/hong-kong-stocks-waver-chinas-mixed-economic-data-drug-companies-lead-decline?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3314547/hong-kong-stocks-waver-chinas-mixed-economic-data-drug-companies-lead-decline?utm_source=rss_feed Mon, 16 Jun 2025 02:33:26 +0000 Aileen Chuang Aileen Chuang Hong Kong stocks dropped on Friday as rising geopolitical tensions dimmed investor appetite for risk assets. The Hang Seng Index fell 0.6 per cent to 23,892.56, though it notched a small gain of 0.4 per cent for the week following a temporary de-escalation of US-China trade tensions. The Hang Seng Tech Index fell 1.7 per cent. On the mainland, the CSI 300 Index dropped 0.7 per cent and the Shanghai Composite Index retreated 0.8 per cent. Sino Biopharmaceutical pared its Thursday gains by falling... https://www.scmp.com/business/markets/article/3314243/hong-kong-stocks-fall-slightly-rising-geopolitical-tensions?utm_source=rss_feed https://www.scmp.com/business/markets/article/3314243/hong-kong-stocks-fall-slightly-rising-geopolitical-tensions?utm_source=rss_feed Fri, 13 Jun 2025 02:29:00 +0000 Aileen Chuang Aileen Chuang Hong Kong stocks fell on Thursday, following declines in the US, as investors grappled with new trade threats from Washington and uncertainty over trends in interest rates. The Hang Seng Index dropped 1.4 per cent to 24,035.38, wiping out Wednesday’s gains that followed a preliminary US-China trade agreement. The Hang Seng Tech Index lost 2.2 per cent. On the mainland, the CSI 300 Index fell 0.1 per cent and the Shanghai Composite Index was mostly flat. Technology stocks weighed on Hong Kong’s... https://www.scmp.com/business/markets/article/3314090/hong-kong-stocks-fall-us-trade-threats-and-interest-rate-uncertainty?utm_source=rss_feed https://www.scmp.com/business/markets/article/3314090/hong-kong-stocks-fall-us-trade-threats-and-interest-rate-uncertainty?utm_source=rss_feed Thu, 12 Jun 2025 02:21:38 +0000 Dannie Peng Dannie Peng The US Food and Drug Administration (FDA) has approved the first China-invented painkiller designed as a non-opioid alternative, giving it the potential to curb fentanyl-related overdose deaths. Qamzova, developed by Nanjing-based biotech firm Delova, is the world’s first long-acting injectable analgesic – offering 24-hour pain relief through a single daily injection and marking a milestone for China’s growing pharmaceutical industry. The non-steroidal anti-inflammatory (NSAID) medication... https://www.scmp.com/news/china/science/article/3311295/us-approves-china-invented-painkiller-could-reduce-fentanyl-overdoses?utm_source=rss_feed https://www.scmp.com/news/china/science/article/3311295/us-approves-china-invented-painkiller-could-reduce-fentanyl-overdoses?utm_source=rss_feed Fri, 23 May 2025 11:00:09 +0000 Zhang Shidong Zhang Shidong Hong Kong stocks rose on Tuesday, with the benchmark climbing to a two-month high after China cut key interest rates for the first time in seven months. The Hang Seng Index closed 1.5 per cent higher at 23,681.48, a level not seen since March 24. The Hang Seng Tech Index added 1.2 per cent. On the mainland, the CSI 300 Index climbed 0.5 per cent and the Shanghai Composite Index advanced 0.4 per cent. Morgan Stanley’s upbeat view on China’s pharmaceutical industry boosted drug makers, which led... https://www.scmp.com/business/china-business/article/3310996/hong-kong-stocks-rise-after-china-cuts-borrowing-costs-first-time-7-months?utm_source=rss_feed https://www.scmp.com/business/china-business/article/3310996/hong-kong-stocks-rise-after-china-cuts-borrowing-costs-first-time-7-months?utm_source=rss_feed Tue, 20 May 2025 02:17:47 +0000 Shi Huang Shi Huang A new medication has shown promise as a safe and effective therapy for a hard-to-treat type of lung cancer, according to an international clinical trial led by Chinese and US scientists. The findings were published in the New England Journal of Medicine (NEJM) on April 28 and presented at the American Association for Cancer Research Annual Meeting in Chicago on the same day. The researchers found that the oral medication zongertinib outperformed the standard treatment option when treating... https://www.scmp.com/news/china/science/article/3309862/drug-trial-offers-hope-patients-hard-treat-lung-cancer-china-us?utm_source=rss_feed https://www.scmp.com/news/china/science/article/3309862/drug-trial-offers-hope-patients-hard-treat-lung-cancer-china-us?utm_source=rss_feed Sun, 11 May 2025 03:00:21 +0000 Sino Biopharmaceutical on Monday announced a US$515 million investment in Covid-19 vaccine developer Sinovac Life Sciences, as the Beijing-based generic drug maker seeks to expand its reach into vaccine development and sales. The Hong Kong-listed company agreed to buy a 15 per cent stake in Sinovac Life Sciences, a unit of Nasdaq-listed pharmaceutical firm Sinovac Biotech. “The board believes the capital contribution will introduce a key strategic partner to the group and expects that both... https://www.scmp.com/business/companies/article/3112855/sino-biopharm-secures-room-future-growth-us515-million?utm_source=rss_feed https://www.scmp.com/business/companies/article/3112855/sino-biopharm-secures-room-future-growth-us515-million?utm_source=rss_feed Mon, 07 Dec 2020 07:18:41 +0000 Good day, traders -- Hong Kong and China markets had an afternoon case of jitters. Catch up on the action below. Don't miss out on our live coverage of Hong Kong and mainland markets each trading day! If you would like the Live Stocks Blog emailed to you each morning, click here.  -- Kathleen Magramo and Deb Price in Hong Kong  Note: Information in this blog is on an "as is" basis and not a solicitation or offer to buy or sell any securities or otherwise; and is not investment/professional... https://www.scmp.com/business/article/3064696/asia-markets-get-boost-coming-phone-call-worlds-top-finance-leaders?utm_source=rss_feed https://www.scmp.com/business/article/3064696/asia-markets-get-boost-coming-phone-call-worlds-top-finance-leaders?utm_source=rss_feed Tue, 03 Mar 2020 01:21:20 +0000 An index that tracks shares of mainland Chinese companies on the Hong Kong stock exchange will admit a pharmaceutical stock and a utility, index compiler Hang Seng Indexes said on Friday. The companies replace a railway company and a building materials producer, partly reflecting the changing profile of China’s economy. Sino Biopharmaceutical and China Resources Gas Group will replace the H shares of China Railway Group and China National Building Material on the Hang Seng China Enterprises... https://www.scmp.com/business/banking-finance/article/3036992/sino-biopharmaceutical-added-hong-kong-index-chinese?utm_source=rss_feed https://www.scmp.com/business/banking-finance/article/3036992/sino-biopharmaceutical-added-hong-kong-index-chinese?utm_source=rss_feed Sat, 09 Nov 2019 01:00:13 +0000 Sino Biopharmaceutical’s billionaire founder and his wife are transferring about one-fifth of the company’s share capital, or around US$3.8 billion, to their son – as a gift. The grant of 2.7 billion shares, detailed in a Hong Kong exchange filing late Tuesday, makes Eric Tse one of Asia’s richest individuals overnight. (There’s no tax on gifts or inherited wealth in the former British colony.) But the 24-year-old son of Tse Ping and Cheng Cheung Ling says he’ll try to keep a low... https://www.scmp.com/business/companies/article/3034346/sino-biopharmaceutical-founders-son-who-parties-and-takes?utm_source=rss_feed https://www.scmp.com/business/companies/article/3034346/sino-biopharmaceutical-founders-son-who-parties-and-takes?utm_source=rss_feed Thu, 24 Oct 2019 04:40:22 +0000